Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate is a clinical-stage biopharmaceutical company that utilizes its drug delivery platform technology to develop once-daily tablets of multi-dose therapies, with an initial focus on ADHD and anxiety. While receiving a Complete Response Letter from the FDA for its lead asset, CTx-1301, is not ideal, the lack of safety or efficacy concerns bodes well for potential future approval after addressing Chemistry, Manufacturing and Controls (CMC) requests. With a current valuation that is attractive and the potential for significant upside, the risks of balance sheet/liquidity concerns, regulatory approvals, and competition should be considered. The company's focused approach on ADHD and its strong pipeline of potential treatments in this area, along with commercial readiness initiatives, make it a promising investment opportunity.

Bears say

Cingulate is facing an uphill battle with their ADHD and anxiety-focused drug delivery products, as evidenced by a lowered EPS estimate to $(1.81), with recent raising of funds likely only sustaining operations until 2027. Despite this market potential being quite large and the estimated ADHD medication sales growing year-over-year, the company's strength in this space is uncertain and could lead to a negative outlook on their stock.

Cingulate (CING) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.